Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: Expression profile of SKP2 in different tumor samples and normal tissues. ( A ) GEPIA analysis of TCGA and GTEx datasets showed that SKP2 expression was generally elevated in multiple tumor types compared with normal tissues. ( B ) In glioma, SKP2 mRNA levels were significantly higher in GBM compared with normal brain tissues, while the difference in LGG was not statistically significant.* p < 0.05.

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques: Expressing

Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: Relationship between SKP2 and clinicopathologic features and prognosis of glioma. ( A ) Characteristics of the overall distribution of SKP2-related clinicopathological features of glioma in The Cancer Genome Atlas (TCGA) dataset. ( B ) The overall distribution characteristics of glioma SKP2-related clinicopathological features in the Chinese Glioma Genome Atlas (CGGA) dataset. ( C ) and ( G ), SKP2 was significantly elevated in high-grade gliomas in the TCGA and CGGA Cohort1 datasets. ( D ) and ( H ), in the TCGA and CGGA Cohort1 datasets, SKP2 was significantly elevated in gliomas without isocitrate dehydrogenase (IDH) mutations. ( E ) and ( I ), SKP2 was significantly increased in gliomas without 1p/19q codeletion in the TCGA and CGGA Cohort1 datasets. ( F ) and ( J ), SKP2 is elevated in gliomas unmethylated with the O6-methylguanine-DNA methyltransferase (MGMT) promoter. This difference was statistically significant in the TCGA dataset but not in the CGGA Cohort1 dataset.

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques:

Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: GO analysis and GSEA enrichment analysis of SKP2-related genes. SKP2 positively correlated genes (TCGA ( A ), CGGA Cohort1 ( C )) were analyzed by GO. The best enrichment pathways (TCGA ( B ), CGGA ( D )) were identified by GSEA. SKP2 is closely related to the regulation of cell cycle processes. ( E ) and ( F ), correlation analysis of SKP2 expression and cell cycle checkpoints in TCGA and CGGA Cohort1 datasets. Pathway data were obtained from the KEGG database (Kanehisa Laboratories).

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques: Expressing

Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: Validation of the SKP2 risk score in the CGGA Cohort1 dataset. ( A ) Distribution of risk scores, overall survival (OS), and expression levels in the CGGA Cohort1 dataset. ( B ) Kaplan–Meier survival analysis of risk scores in patients with glioma in the CGGA Cohort1 dataset. ( C ) Receiver Operating Characteristic (ROC) curve analysis at time, predicting 1, 3, and 5-year OS based on risk scores from the CGGA Cohort1 dataset.

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques: Biomarker Discovery, Expressing

Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: Knockdown efficiency of SKP2 in glioma cells. ( A ) Western blot showing SKP2 expression in U87 cells after transfection with si-NC, si-SKP2-1, or si-SKP2-2. β-actin was used as a loading control. Quantification of relative SKP2 expression is shown below. ( B ) Western blot analysis of U251 cells with the same treatments. Quantification shows that both siRNAs reduced SKP2 expression, with si-SKP2-1 showing the highest efficiency, which was used for further experiments. Statistical analysis was performed using Student’s t-test (two groups) or one-way ANOVA (multiple groups). **** p < 0.0001.

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques: Knockdown, Western Blot, Expressing, Transfection, Control

Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: Flow cytometry and Western blot assay were used to verify that SKP2 regulates the cell cycle. ( A ) Flow cytometry to detect the cell cycle. ( B ) Changes in cell cycle phases after SKP2 knockdown. ( C ) Western blot experimental results. ( D ) Changes in key cell cycle proteins after SKP2 knockdown. The data were obtained from three independent experiments. Statistical analysis was performed using Student’s t-test. * p < 0.05.

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques: Flow Cytometry, Western Blot, Knockdown

Journal: Scientific Reports

Article Title: SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle

doi: 10.1038/s41598-025-26722-6

Figure Lengend Snippet: SKP2 knockdown suppresses tumor growth in vivo. ( A ) Representative bioluminescence images of nude mice bearing subcutaneous xenografts of U87 cells stably expressing sh-NC or sh-SKP2 at day 25 post-injection. The sh-SKP2 group showed markedly reduced luminescence signal. ( B ) Body weight curves showing no significant difference between groups throughout the experiment. ( C ) Quantification of bioluminescence intensity demonstrating significantly reduced tumor burden in the sh-SKP2 group. ( D ) Representative photographs of excised tumors at day 25, showing smaller tumor size in the sh-SKP2 group. ( E ) Tumor growth curves measured every 5 days showing significantly slower growth in the sh-SKP2 group. ( F ) Tumor weight at sacrifice was significantly lower in the sh-SKP2 group. ( G ) Western blot analysis of tumor lysates confirming reduced SKP2 expression and corresponding decreases in Cyclin E and CDK2 levels in sh-SKP2 tumors. β-actin served as loading control. Quantification of three independent tumors per group is shown below. Statistical analysis was performed using Student’s t-test. Error bars represent mean ± SEM. *** p < 0.001, **** p < 0.0001.

Article Snippet: The membrane was blocked in 5% fetal bovine serum and incubated overnight at 4 °C with the following primary antibodies: SKP2 (Rabbit mAb, Abconal, A4046, 1:1000), CDK2 (Proteintech, 10,122–1-AP, 1:2000), Cyclin E1 (Affinity, AF0144, 1:1000), and β-actin (Proteintech, 20,536–1-AP, 1:5000).

Techniques: Knockdown, In Vivo, Stable Transfection, Expressing, Injection, Western Blot, Control